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Since the pioneering studies of Heppner and co-workers on mouse 
mammary cancer [1], the presence of heterogeneous phenotypes and 
genotypes within the cancer bulk has been clearly demonstrated in several 
types of malignancies [2].
Different co-existing sub-populations, arising from both genetic and 
non-genetic variability and providing both heritable and non-heritable 
clones, give rise to an organized community in which not only cooperative 
but also conflicting interactions may set up. The resulting clonal crosstalk 
guarantees tumour growth, helping its spread through metastasis and 
the emergence of resistance to the commonly exploited anti-cancer 
treatments.
Although aware of tumour heterogeneity [2-6], we are still far from 
understanding how different phenotypes and genotypes interact, thus 
allowing the whole community to survive therapeutic selection and/
or suppression. This is why we failed so far to fine-tune a long-lasting, 
effective treatment for this kind of pathology. Accordingly, untangle 
tumour complexity is a basic and urgent challenge scientists should not 
work around anymore.
Different kinds of cancer heterogeneity exist, regarding both inter-
tumour and intra-tumour differences (Figure 1) [7]. Malignancies 
belonging to the same histopathological subtype but affecting different 
patients show genetic diversity, and are characterized by divergent 
functional behaviours. At the same time, malignancy affecting the 
same patient shows a marked variation too: the tumour bulk harbours 
both phenotypically and genotypically different cell populations (spatial 
heterogeneity), and heterogeneity may also arise when serial samples 
from the same patient are examined within the entire disease course 
(temporal heterogeneity).
A number of players take part to this heterogeneous tumour 
architecture. The main portion of the tumour bulk is made up of rapidly 
cycling and terminally differentiated cancer cells, but a small percentage 
of cells co-exist, bearing stem-like properties, whose origin is still a matter 
of debate [8-10]. They have been described as either arising from normal 
stem cells, as a result of epigenetic mutations, or deriving from more 
differentiated cells, which have acquired self-renewing ability through 
genetic modifications. As an alternative, Cancer Stem Cells (CSCs) may 
be generated by an Epithelial-to-Mesenchymal Transition (EMT), which 
allows the existing neoplastic cells to acquire mesenchymal traits and 
express stem-cell markers.
According to the hierarchical model of tumorigenesis, the so called 
‘cancer stem cell theory’, CSCs play a key role in tumour perpetuating and 
progression, thanks to their indefinite self-renewal ability and aberrant 
differentiation capacity [11].
Moreover, differently from the bulk cells, CSCs resist to chemotherapy 
and radiotherapy. Indeed, cytotoxic treatments commonly exploited 
to target rapidly dividing cells are rather ineffective against this specific 
cancer sup-population, as it is characterized by a slow mitotic activity 
possibly associated with a quiescent G0/G1 state. Therefore, rather than 
being eradicated, CSCs turn out to be selected over the cancer bulk, being 
free to drive tumour relapse and mediate metastasis [12-16].
It is now clear that both CSCs and the non-stem differentiated tumor 
cells exist in a dynamic equilibrium, as the former can differentiate 
through asymmetric division and the latter can acquire CSC-like state. 
Any shift in this balance leads to a more CSC-rich tumor, which increases 
its aggressiveness worsening patients’ prognosis.
The reversible and highly plastic stem-like state is modulated by 
micro environmental signals arising in the tumor niche [17-20]. Indeed, 
microenvironment surrounding the tumour bulk and comprising 
non-neoplastic cells like fibroblasts, adipocytes, infiltrating immune/
inflammatory cells, as well as vessels and associated matrix, does not play 
a mere role of scaffold but rather participates actively in tumour growth 
modulation through both stimulatory and inhibitory signalling, thus 
further ravelling tumour complexity.
Bearing in mind the overall picture, a fruitful treatment of tumour 
should not ignore a careful selection of patients, made on the analysis of 
both tumour cells types and microenvironment hallmarks. In particular, 
the commonly available sequencing technologies should be used at 
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Figure 1: Inter-tumour and Intra-tumour Heterogeneity
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diagnosis, to mark tumour heterogeneity, but also thereafter, to monitor 
cell differentiation during treatment response and point out the possible 
emergence of drug resistance during disease progression. Accounting for 
heterogeneity allows to choose the best personalized therapeutic approach 
which, in turn, should necessary combine agents targeting cancer’s growth 
and survival, focusing in particular on CSCs, with derivatives targeting 
tumour microenvironment. Complementarity in the mechanism 
of actions of different compounds may merge, in principle, the best 
functional response with the lowest risk of drug resistance, thus helping to 
achieve a plain recovery.
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